Hypoxia and oxidant stress with cerebrovascular failure and effective ways to correct them

Authors:
E.I. CHUKANOVA, A.S. CHUKANOVA, D.M. RODIONOVA

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY 2022, Vol. 122, No. 8

Abstract:
Cerebrovascular diseases (CVD) are one of the most common causes of cognitive impairment. The development of CVD is associated with key cardiovascular risk factors, leading to hypoxia, oxidative stress, mitochondrial and endothelial dysfunction, and ultimately apoptosis, leading to degenerative changes in the brain. Hypoxia and oxidative stress are key mechanisms in the development of CVD, necessitating the use of agents with antihypoxic and antioxidant activity. Mexidol (ethylmethylhydroxypyridine succinate) is one such agent. Mexidol directly impacts the pathogenetic factors that contribute to ischemic-hypoxic brain injury and is highly clinically effective in the treatment of various forms of CVD.

Key words: chronic cerebrovascular insufficiency, hypoxia, oxidative stress, vascular cognitive impairment, endothelial dysfunction, mexidol.